We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Risk of suboptimal hormone replacement therapy for young hypogonadal women and transgender women in the wake of the Joint BMS FSRH RCGP RCOG SfE and RCN Women's Health Forum safety alert.
- Authors
Mamoojee, Yaasir; Mitchell, Anna L.; Quinton, Richard
- Abstract
These groups do not fall within the remit of product licensing for existing oestrogen and progestogen preparations, because no HRT products have been specifically developed for these patients and, therefore, the available clinical trial data for women going through the natural menopause at a mean age of 51 years should not be extrapolated to them. The British Menopause Society (BMS) has recently produced a joint statement, supported by a number of other professional bodies and societies - including the Society for Endocrinology - on the safety and appropriate dosing of oestrogen and progestogen hormone replacement therapy (HRT) provided to menopausal women to alleviate symptoms of menopause.[1] It rightly stipulates that postmenopausal women should be treated within established guidelines and the current marketing authorizations of licensed HRT products. Clinicians and Primary Care colleagues should be advised that HRT prescription for younger patients with POI (<40 years of age) or central hypogonadism and transgender women do not fall within the specified advice in the BMS joint statement.
- Subjects
CANADA. Royal Canadian Navy; TRANS women; WOMEN'S health; HORMONE therapy; YOUNG women; PREMATURE menopause; PREMATURE ovarian failure
- Publication
Clinical Endocrinology, 2023, Vol 99, Issue 3, p326
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1111/cen.14937